| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23023 |
| Drug | Mosunetuzumab |
| Brand | Lunsumio® |
| Indication | Mosunetuzumab (Lunsumio®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. |
| Assessment Process | |
| Rapid review commissioned | 27/04/2023 |
| Rapid review completed | 25/05/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mosunetuzumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/05/2023 |
| Pre-submission consultation with Applicant | 04/07/2023 |
| Full submission received from Applicant | 22/02/2024 |
| Preliminary review sent to Applicant | 22/10/2024 |
| NCPE assessment re-commenced | 18/11/2024 |
| Follow-up to preliminary review sent to Applicant | 11/12/2024 |
| NCPE assessment re-commenced | 18/12/2024 |
| Factual accuracy sent to Applicant | 20/02/2025 |
| NCPE assessment re-commenced | 25/02/2025 |
| Follow up to factual accuracy check sent to Applicant | 28/02/2025 |
| NCPE assessment re-commenced | 03/03/2025 |
| NCPE assessment completed | 24/03/2025 |
| NCPE assessment outcome | The NCPE recommends that mosunetuzumab not be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
